A
DYN icon

AlphaQuest’s Dyne Therapeutics DYN Stock Holding History

AlphaQuest’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,963
Closed -$312K – 613
2025
Q4 		$312K Buy
15,963
+1,311
+9% +$24.8K 0.02% 1182
2025
Q3 		$185K Sell
14,652
-3,665
-20% -$41.8K 0.01% 1444
2025
Q2 		$174K Buy
18,317
+1,985
+12% +$21.9K 0.02% 1213
2025
Q1 		$171K Buy
+16,332
New +$234K 0.02% 1060
2024
Q4 		– Sell
-3,434
Closed -$123K – 1782
2024
Q3 		$123K Buy
3,434
+3,090
+898% +$123K 0.01% 1236
2024
Q2 		$12.1K Buy
344
+179
+108% +$5.2K ﹤0.01% 1313
2024
Q1 		$4.68K Sell
165
-1,217
-88% -$27.5K ﹤0.01% 1100
2023
Q4 		$18.4K Buy
+1,382
New +$13.5K ﹤0.01% 968

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

AlphaQuest's DYN Position: Q1 2026 in Review

AlphaQuest sold out of Dyne Therapeutics (DYN) in Q1 2026, closing a stake of 15,963 shares — an estimated $312K sold.

AlphaQuest first reported a position in DYN in Q4 2023 and held it in 8 quarters. The position peaked at $312K in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • AlphaQuest reported no remaining Dyne Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 15,963 Dyne Therapeutics shares in Q1 2026, an estimated $312K.
  • AlphaQuest first reported a position in Dyne Therapeutics in Q4 2023 and held it in 8 quarters.
  • AlphaQuest's Dyne Therapeutics position peaked at $312K in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.